Data Limitations: All information is current as of July 13, 2026 (market close). Stock prices, financials, and news are time-sensitive and subject to rapid change. Sources include Yahoo Finance, Agenus Investor Relations, and analyst reports. Past performance does not guarantee future results. This is not investment advice.
Agenus Inc. (AGEN), a clinical-stage immuno-oncology company, has reported promising Phase 1b survival data for its BOT+BAL combination in refractory MSS metastatic colorectal cancer and secured up to $340 million in financing for a pivotal Phase 3 trial, driving an 82.7% single-day stock surge to $6.12 amid strong analyst Buy ratings and positive momentum.
| Metric | Value | Notes |
|---|---|---|
| Closing Price (July 13, 2026) | $6.12 | Up $2.77 (+82.69%) from previous close of $3.35; intraday high $8.70 |
| After-Hours | $6.07 (-0.82%) | Slight pullback post-surge |
| 52-Week Range | $2.71 - $8.70 | Recent highs driven by news |
| Market Cap | ~$254.9M | Post-surge; pre-financing ~$140M |
| Volume | 172.96M shares | Extremely elevated vs. avg. 870K |
Links for more information: Yahoo Finance AGEN Quote | Agenus IR Stock Quote
The surge reflects investor enthusiasm for the strategic pivot and financing, but such volatility is typical for micro-cap biotechs and carries high risk of reversal.
| Period | AGEN Return | S&P 500 Return | Notes |
|---|---|---|---|
| YTD (2026) | +94.90% | +9.79% | Significant outperformance |
| 1-Year | +13.31% | +20.06% | Underperformed benchmark |
| 3-Year | +83.46% | +66.64% | Stronger long-term |
| 5-Year | +94.47% | +72.01% | Volatile history |
Historical returns are highly volatile due to clinical trial outcomes, dilutions, and market sentiment; 2024 saw sharp declines (-83% in one report).
Links: Yahoo Performance | Macrotrends History
| Metric | Value | Notes / Source |
|---|---|---|
| Revenue (TTM) | $123.87M | Primarily non-cash royalties; Q1 2026: $33.7M |
| Net Income (TTM) | $64.39M | Unusual profit for clinical-stage; EPS $2.05 |
| Profit Margin | 52.16% | High due to revenue mix |
| Cash & Equivalents | ~$35M (MRQ) | Pre-$340M financing; Q1 2025 was $18.5M |
| Total Debt | Not fully detailed | Recent extensions of maturities |
| Employees | 81 | Lean operation |
Positive net income may stem from royalty monetization or one-time items rather than product sales; cash runway extended significantly by new financing.
Financials based on latest reported TTM/Q1 2026; full Q2 2026 results expected ~Aug 2026. Clinical-stage companies often burn cash on R&D.
Links: Agenus Quarterly Results | Yahoo Financials
| Consensus | Average Target | Range | Recent Action |
|---|---|---|---|
| Strong Buy / Buy | $15.50 | $6.00 - $30.00 | HC Wainwright maintains Buy, raises target to $30 (July 13, 2026) |
Links: Yahoo Analysts | Benzinga Ratings
These provide development support, licensing, and potential milestone/royalty revenue.
| Company | Ticker | Focus | Market Cap (approx.) |
|---|---|---|---|
| MiNK Therapeutics (Agenus subsidiary) | INKT | Adoptive cell therapies | ~$56M |
| Iovance Biotherapeutics | IOVA | TIL therapies for cancer | ~$1.8B |
| MacroGenics | MGNX | Antibody-based IO | ~$286M |
| ImmunityBio | IBRX | Immunotherapies | Not specified |
| Myriad Genetics | MYGN | Diagnostics / oncology | Not specified |
Agenus differentiates via broad antibody platform and specific BOT (Fc-enhanced CTLA-4) + BAL (PD-1) combo; competition intense in IO space.
Overview (Fact): Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Headquartered in Lexington, Massachusetts (founded 1994 as Antigenics Inc.; renamed 2011). Employs ~81 people. Key platforms: Retrocyte Display for antibodies, QS-21 Stimulon adjuvant. Lead assets: botensilimab (BOT, AGEN1181 - Fc-enhanced CTLA-4) and balstilimab (BAL - PD-1).
History (Fact): Established 1994 with focus on immune modulation. Evolved to comprehensive IO pipeline including antibodies, cell therapies (via MiNK subsidiary), and adjuvants (SaponiQx). Multiple partnerships and clinical advancements over 30+ years; faced typical biotech challenges including cash burn and dilutions.
Future success hinges on clinical trial outcomes and regulatory approvals, which are inherently uncertain.
Links: Company Website | IR Overview
Recent data and financing signal a focused late-stage push in colon cancer, potentially transformative if successful.
Links: Agenus Press Releases | Yahoo News
Key Uncertainties & Assumptions: Clinical success of BOT+BAL in Phase 3 is not guaranteed (high failure rate in oncology). Financing involves potential dilution via warrants. Revenue largely royalty-based; sustainable product revenue uncertain. Market caps and prices fluctuate intraday. Data aggregated from public sources; verify with primary filings (10-Q/10-K) for completeness. Biotech stocks carry substantial risk of loss.
More Resources: SEC Filings via EDGAR | ClinicalTrials.gov for pipeline updates.